Catalent Pharma Solutions, with the slogan "more products. better treatments. reliably supplied. ™," is a leading global player in the biotechnology, manufacturing, and pharmaceutical industries. Founded in 2007 and headquartered in the United States, it has become an S&P 500® company with a focus on enabling pharma, biotech, and consumer health partners to optimize product development and launch, along with full life-cycle supply for patients worldwide. Catalent boasts approximately 19,000+ workers supporting over 7,000 products for more than 1,000 customers globally. The company has made a striking $600.00MPost-IPO Debt investment as of 19 December 2023. It positions itself as a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs, introducing around 200 new products and manufacturing over 70 billion doses annually. With its commitment to putting patients first and striving to help people live healthier lives, Catalent combines the concepts of catalyst and talent to signify its role as a catalyst for success. The company's comprehensive expertise, broad offerings, and innovative technologies are aimed at accelerating the time to market for new molecules, improving product performance, and delivering superior, reliable manufacturing and packaging results. The organization actively seeks passionate individuals to join in its mission of developing, manufacturing, and supplying products that enhance lives globally. Through collaboration with innovative pharmaceutical, biotech, and healthcare companies, Catalent offers the opportunity for personal growth and the chance to make a significant impact on global health.Visit Catalent Careers to explore existing career opportunities and make a difference in the world of medicine.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Post-IPO Debt | $600.00M | - | 19 Dec 2023 | |
Post-IPO Debt | $550.00M | - | 10 Feb 2021 |
No recent news or press coverage available for Catalent Pharma Solutions.